Mesa Laboratories approves restructuring cutting ~40 jobs, targets $9.3M annualized savings

MESA LABORATORIES INC /CO/

Board approved the Restructuring Program on October 6, 2026; ~40 positions eliminated (~6% of employees), concentrated in Clinical Genomics plus corporate functions.
Estimated pre-tax charges of $2.6M-$3.4M, including $2.3M-$3.0M employee costs; cash expenditures of $2.9M-$3.7M, mostly within 12 months.
Savings Plan targets ~$9.3M in annualized cost reductions with ~$4.3M reinvested, for a net ~$5.0M reduction fully reflected by end of FY2028.
Hamburg, Germany facility will be exited when its lease expires in February 2027; San Diego, California footprint also reduced.
CEO Siddhartha Kadia said Clinical Genomics will focus on pharmacogenomics and oncology at scale, accepting lower revenue for higher gross margin; Q2 FY2027 results set for November 9, 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.